Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification.
AuteursBorys K, Haubold J, Keyl J, Bali MA, De Angelis R, Boni KB, Coquelet N, Kohnke J, Baldini G, Kroll L, Schramm S, Stang A, Malamutmann E, Kleesiek J, Kim M, Kasper S, Siveke JT, Wiesweg M, Merkel-Jens A, Schaarschmidt BM, Gruenwald V, Bauer S, Oezcelik A, Bölükbas S, Herrmann K, Kimmig R, Lang S, Treckmann J, Stuschke M, Hadaschik B, Umutlu L, Forsting M, Schadendorf D, Friedrich CM, Schuler M, Hosch R, Nensa F
Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR.
AuteursÖcal O, Zech CJ, Bali MA, Pasquier D, Mottaghy F, Einspieler I, Kartalis N, Bargellini I, Iezzi R, Denecke T, Kunz WG, Gebauer B, Wege H, Cannella R, Oprea-Lager DE, Vogel A, Sangro B, Seidensticker M
Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.
AuteursKwong JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Ringa M, Feifer A, Lajkosz K, Wettstein MS, Chan A, Lee T, Nguyen M, Kassouf W, Black PC, Breau RH, Lodde M, Fairey A, Lattouf JB, Jeldres C, Rendon R, Alimohamed N, Fleshner NE, Diamand R, Gontero P, Sylvester RJ, van Rhijn BWG, Kamat AM, Johnson AEW, Zlotta AR, Kulkarni GS
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.
AuteursBergiers I, Köse MC, Skerget S, Malfait M, Fourneau N, Ellis JC, Vanhoof G, Smets T, Verbist B, De Maeyer D, Van Houdt J, Van der Borght K, Verona R, Heidrich B, Kurth W, Delforge M, Meuleman N, Van Droogenbroeck J, Vlummens P, Heuck CJ, Beguin Y, Bahlis N, Casneuf T, Caers J
Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM project.
AuteursHillen B, Oestreicher G, Schwab L, Enders K, Simon P, Elme A, Ben-Aharon I, Goshenlago T, Neuzillet C, Sclafani F, Beltran EEM, Schuster M, Doncheva H, Ruckes C, Karlecik M, Petrowski K, Rosenbaum D, Diou C, Ballas A, Vlachostergiou A, Mastricci D, Scherrer A, Pilz M, Flechsig J, Apostolidis L, Krooupa AM, Chintha S, Musisi IW, Tzavara NP, Kakasis A, Hadjikypri X, Karra S, Chatzipanagiotou K, Drivas I, Dacasa H, Moehler M
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
AuteursModi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D
